GlassScriptPhysician profile
Babu Subramaniam
NPI 1306808258
$631.78
in general payments reported to CMS, 2019-2025
13 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $102 · 2024: $340 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $102.18 | 2023 | Amplatzer Talisman |
| Abbvie INC. | $94.29 | 2025 | |
| Tg Therapeutics, INC. | $78.31 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $60.33 | 2024 | Austedo Xr |
| Acadia Pharmaceuticals INC | $55.43 | 2024 | Nuplazid |
| Genzyme Corporation | $48.93 | 2025 | |
| Kyowa Kirin, INC. | $48.80 | 2024 | Nourianz |
| Pfizer INC. | $28.90 | 2024 | |
| Lundbeck LLC | $24.82 | 2024 | Vyepti |
| Sk Life Science, INC. | $23.32 | 2024 | |
| Celgene Corporation | $23.29 | 2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $22.11 | 2024 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $21.07 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babu Subramaniam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.